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Attitudinal barriers towards analgesic use among primary care patients with chronic pain and substance use disorders (SUDs)
are not well understood. We evaluated the prevalence of moderate to signiﬁcant attitudinal barriers to analgesic use among 597
primary care patients with chronic pain and current analgesic use with 3 subscales from the Barriers Questionaire II: concern
about side eﬀects, fear of addiction, and worry about reporting pain to physicians. Concern about side eﬀects was a greater barrier
for those with opioid use disorders (OUDs) and non-opioid SUDs than for those with no SUD (OR (95% CI): 2.30 (1.44–3.68),
P<0.001and1.64(1.02–2.65),P = 0.041,resp.).FearofaddictionwasagreaterbarrierforthosewithOUDsascomparedtothose
with non-opioid SUDs (OR (95% CI): 2.12 (1.04–4.30), P = 0.038) and no SUD (OR (95% CI): 2.69 (1.44–5.03), P = 0.002).
Conversely, participants with non-opioid SUDs reported lower levels of worry about reporting pain to physicians than those with
noSUD(OR(95%CI):0.43(0.24–0.76),P = 0.004).ParticipantswithOUDsreportedhigherlevels ofworryaboutreportingpain
than those with non-opioid SUDs (OR (95% CI): 1.91 (1.01–3.60), P = 0.045). Concerns about side eﬀects and fear of addiction
can be barriers to analgesic use, moreso for people with SUDs and OUDs.
1.Introduction
Chronic pain is commonly encountered in primary care [1],
where the majority of patients with substance use disorders
(SUDs) receive health care [2]. Patients with SUDs are at
signiﬁcantriskofpain[3,4]andarelikelytobeundertreated
for pain. Not only do patients with SUDs report continued
pain despite engaging in medical care [5], but few providers
caring for these patients follow recommended guidelines [6].
Manypathways may be responsible for such undertreatment,
from health systems issues, like insurance coverage and
limited access to specialists, to clinician attitudes and skills
[7].Forexample,cliniciansmaybeappropriatelyreluctantto
prescribe opioid pain medications to patients with histories
of substance use disorders out of concern that patients
may divert or misuse them [8]. One possible and relatively
unexplored reason for undertreatment is patient attitudinal
barriers to analgesic medications, such as concerns about
side eﬀects, fear of addiction, and worries about reporting
pain to physicians. Indeed, patients with SUDs who are HIV
positiveorareenrolledinmethadonemaintenanceprograms
report signiﬁcant attitudinal barriers to pain medications,
including concerns regarding addiction potential, need for
escalating doses, and diﬃculty communicating with their
clinicians regarding pain [9, 10]. However, such attitudinal
barriers to analgesic use, such as opioid medication use,
among patients with SUDs in primary care settings have not
been well described.
Several patient characteristics have been associated with
attitudes that may result in more barriers to the use of anal-
gesic medications (i.e., higher attitudinal barriers) including
non-White race, lower education, more physical symptoms2 Pain Research and Treatment
[10], older age [11], higher pain severity and disability [12],
unemployment [13], and depression [14], while the data on
gender are mixed [13, 15]. Other characteristics have not
been explored but seem likely to impact attitudinal barriers,
such as whether patients are currently or previously addicted
to substances, the substances to which they may be addicted
(e.g., opioids versus nonopioid drugs), and recent use of
analgesics. For example, patients with past addiction, who
are currently in recovery, may have more negative attitudes
about opioid analgesics than those currently addicted.
Similarly, patients with opioid use disorders (OUDs) may
be more likely than patients with nonopioid SUDs to have
negative attitudes regarding the addiction potential of opioid
pain medications. Finally, though psychiatric illnesses, such
as depression and anxiety, are known to be associated
with more attitudinal barriers [14], the ways in which
other psychiatric illnesses, like posttraumatic stress disorder,
commonamongpeoplewithchronicpain[16,17]andSUDs
[18], aﬀect attitudinal barriers has not yet been explored.
Our objective was to compare attitudinal barriers to
analgesic use among patients with SUDs and those without,
across three domains: concern about side eﬀects, fear of
addiction, and worries about reporting pain to physicians.
We hypothesized that the majority of primary care patients
with SUDs would have moderate-to-severe attitudinal bar-
riers and that those with SUDs would have greater barriers
in all three domains as compared to those without SUDs.
We also explored whether two subcategories of SUDs—
(1) current versus lifetime disorder and (2) OUD versus
nonopioid SUD—report greater barriers. We hypothesized
thatpeoplewithlifetimeSUDsascomparedtocurrentSUDs,
and OUDs as compared to nonopioid SUDs, would have
greater barriers in all three domains.
2.MaterialsandMethods
2.1. Participants and Setting. We conducted a cross-sectional
study of a sample of primary care patients with chronic
pain. We recruited participants between February 2005 and
August 2006 from waiting rooms of an academic, urban
hospital primary care practice. We approached patients
waiting for appointments and included patients who were
18–60 years of age, spoke English, had pain for three months
or more, reported use of any analgesic medication (over-
the-counter or prescription) in the prior month, and had
a scheduled primary care appointment. Informed consent
was obtained from eligible patients. Trained interviewers
administered surveys. We compensated participants with
$10. The Boston University Medical Center Institutional
Review Board approved the study, and a certiﬁcate of
conﬁdentiality was obtained from the National Institutes of
Health.
2.2. Instruments
Dependent Variables. The dependent variables of interest
were the Barriers Questionnaire II (BQ-II) subscale scores.
The BQ-II, a validated 27-item self-report survey, was origi-
nally designed to measure barriers to obtaining pain relief
f o rc a n c e rp a t i e n t s[ 11]. We selected the BQ-II because
it is a widely used instrument and has been adapted for
use with adolescent cancer patients [19] and HIV/AIDS
populations [10], and is used in ambulatory settings [10,
19]. We eliminated all questions referring to cancer pain
and the immune system in order to make it applicable to
a primary care population. The resulting 9-item version,
displayed in Table 1, contains three subscales including
concern about side eﬀects, fear of addiction, and worries
about reporting pain to physicians. The questionnaire refers
to“painmedications”anddoesnotspecifyopioidanalgesics.
The items are scaled on a 6-point Likert scale from 0 (do
not agree) to 5 (agree very much). A-one point increase on
the overall BQ-II has previously been shown to be associated
with a twofold greater likelihood of being undermedicated
for pain control [10]. A BQ subscale score cutoﬀ of ≥3h a s
been previously used in the literature [10]; we considered
as c o r eo f≥3 to be indicative of moderate-to-signiﬁcant
barriers.
Independent Variables. The main independent variables of
interest were mutually exclusive categories of substance
use disorders identiﬁed using the Composite International
Diagnostic Interview v. 2.1 Drug Use Disorder module, a
well-validated interview instrument that yields current and
past DSM-IV diagnoses [20, 21].
We assigned participants into three mutually exclusive
categories of substance use disorders: those with “OUDs”
(which included opioid abuse and dependence), “nonopioid
SUDs” (met criteria for a substance use disorder but not an
OUD—includes abuse and dependence on alcohol or other
drug) and no SUD. If a participant met criteria for more
than one substance use disorder and one was opioids, we
categorized them as “OUD.’’
Covariates. We adjusted analyses for factors known to be
associated with attitudinal barriers to analgesic use [11,
13–15], or, in the absence of data, due to clinical sus-
picion that a factor might be associated with attitudinal
barriers. These factors were (1) sociodemographic vari-
ables including sex, race/ethnicity (Black/African American,
Hispanic/Latino/Other, White), employment (unemployed,
includingreceivingdisabilitypaymentsversusemployedpart
or full time), education (<high school, high school+); (2)
depression (major or other versus none) determined by the
Patient Health Questionnaire (PHQ) for Depression, a 9-
item validated measure correlated with past two-week major
depression [22]; (3) somatic symptom severity (high versus
others) determined by the Patient Health Questionnaire-
15, a validated measure that correlates with somatization
disorder [23]; (4) a lifetime history of posttraumatic stress
disorder (PTSD) diagnosis derived from the CIDI v. 2.1
PTSD module [20]; (5) opioid prescription in the past year.
We determined the proportion of participants meeting Pre-
scription Drug Use Disorder (PDUD), deﬁned as any opiate
use disorder that was not heroin alone, but did not include
PDUD as a covariate in the models because it is a subset
of OUD. We determined the proportion of participants with
moderate versus severe pain and disability using the GradedPain Research and Treatment 3
Table 1: Modiﬁed Barriers Questionnaire.
Subscale Item
Side eﬀects
Drowsiness from pain medicine is diﬃcult to
control.
When you use pain medicine, your body
becomes used to its eﬀects and pretty soon it
will not work anymore.
Using pain medicine blocks your ability to
know if you have any new pain.
Pain medicine can keep you from knowing
what is going on in your body.
Addiction
There is a danger of becoming addicted to
pain medicine.
Pain medicine is very addictive.
Reporting pain
to physicians
It is important to be strong by not talking
about pain.
It is important for the doctor to focus on
curing illness, and not waste time controlling
pain.
Doctors might ﬁnd it annoying to be told
about pain.
Chronic Pain Scale [24], a 10-item validated measure of pain
and disability; we did not include pain severity and disability
as a covariate in the models because there is little variation in
this measure (90% reported severe pain).
2.3. Statistical Analysis
Prevalence of Moderate-to-SigniﬁcantBarriers. We compared
the proportion of participants with moderate-to-signiﬁcant
barriers in each category of SUD using chi square analyses.
Current versus Lifetime SUD. We conducted a sensitivity
analysis to examine the relationship between the nonmu-
tually exclusive categories of lifetime (includes both current
and past) and current SUDs, and prevalence of moderate-to-
signiﬁcant barriers. Because we did not detect large diﬀer-
ences, we used lifetime disorders only for subsequent anal-
yses.
OUD versus Nonopioid SUD. We conducted bivariate anal-
yses using general linear models with the Duncan multiple
rangetestfordiﬀerencestoexaminetherelationshipbetween
the independent variable of interest (OUD, nonopioid SUD
and no SUD), and the BQ-II subscale scores. Because
the three categories diﬀered in their relationship to BQ-II
subscalescores(datanotshown),wemaintainedthisvariable
as a three-part variable in further analyses.
Logistic Regression Analysis of Barriers. In bivariate analyses,
the main independent variable impacted the subscales in
opposite directions. We therefore examined the subscales
separately. We ﬁrst conducted bivariate analyses to examine
therelationshipbetweencovariatesandthebarriersubscales.
We then constructed three multivariable logistic regression
models—one for each subscale—in order to examine the
relationship between substance use category (OUD, nono-
pioid SUD, and no SUD) and the odds of having moderate-
to-signiﬁcant barriers. Each model was adjusted for the main
independent variable and all covariates. Tests for colinearity
among the covariates were carried out using correlation
coeﬃcients and any colinear variables were eliminated.
3. Results
3.1. Participant Characteristics. Of 822 eligible patients,
597 (73%) enrolled and completed the research interview.
Enrollees were more likely than those who declined enroll-
ment to be black (61% versus 55%, P = 0.04), less likely
to take over-the-counter pain medication (66% versus 79%,
P<0.001), and more likely to take opioid pain medication
(41% versus 30%, P = 0.002).
Participant characteristicsareshowninTable 2.Amaj o r -
ity of the study sample was female, unemployed, and non-
white. Roughly half of participants had no SUD, one quarter
had an OUD and one quarter had a nonopioid SUD. Of
those with an OUD, 104/138 (75%) met criteria for a
lifetime prescription drug use disorder. As noted in previous
literature [25], the prevalence of OUD is higher among
whites (28%) versus blacks (19%) and among males (32%)
versus females (17%).
3.2. Attitudinal Barriers
Prevalence of Moderate-to-Signiﬁcant Attitudinal Barriers. In
the full sample, moderate-to-signiﬁcant fear of side eﬀects
(60%) and concern about addiction (71%) were common
while worry about reporting pain to physicians was relatively
uncommon (27%). Participants with OUDs more often
reported moderate-to-signiﬁcant fears of addiction than
those with no nonopioid SUDs (89% versus 78%, P = 0.02)
and no SUDs (89% versus 75%, P = 0.01). Participants with
nonopioid SUDs less often reported moderate-to-signiﬁcant
worries about reporting pain to physicians than those with
no SUDs (18% versus 31%, P = 0.01).
Current Versus Lifetime SUD. There were no diﬀerences
in prevalence of moderate-to-signiﬁcant barriers between
those with current and lifetime SUD for any of the subscales
(concern about side eﬀects (66% versus 64%), fear of
addiction (83% versus 78%), and worries about reporting
pain to physicians (23% versus 18%)).
Unadjusted Analyses. Unadjusted logistic regression analy-
ses of moderate-to-signiﬁcant barriers comparing substance
use groups are presented in Table 3.C o n c e r na b o u ts i d e
eﬀects and fear of addiction scores were greater among
participants with OUDs than they were for those with no
SUDs. Similarly, participants with OUDs had greater fear
of addiction than those with nonopioid SUDs. Conversely,
scores reﬂecting worries about reporting pain to physicians4 Pain Research and Treatment
Table 2: Demographic and clinical characteristics of a sample of primary care patients, stratiﬁed by substance abuse (N = 597).
Group
P value Variable OUD Nonopioid SUD No SUD
n = 138 n (%) n = 118 n (%) n = 341 n (%)
Age, mean in years (SD) 45 (8.9) 45 (8.1) 46 (10.4) 0.66
Race/ethnicity <0.0011,2
Black/African American 70 (51%) 71 (61%) 222 (65%)
Hispanic/Latino/Other 25 (18%) 23 (20%) 81 (24% )
White 43 (31%) 23 (20%) 37 (11%)
Gender <0.0011,2
Female 59 (43%) 54 (46%) 237 (70%)
Male 79 (57%) 64 (54%) 104 (31%)
Employment status <0.0011,2
Unemployed or disabled 97 (70%) 83 (70%) 181 (53%)
Full-/part-time 41 (30%) 35 (30%) 160 (47%)
Education 0.56
Less than high school 35 (25%) 37 (31%) 94 (28%)
High school or above 103 (75%) 81 (69%) 247 (72%)
Depression 0.031
Major and/or other 68 (49%) 54 (46%) 127 (37%)
None 70 (51%) 64 (54%) 214 (63%)
Pain severity and disability 0.012
Severe 127 (92%) 113 (96%) 295 (87%)
Moderate 11 (8%) 5 (4%) 46 (13%)
Somatic symptom severity 0.06
High 54 (39%) 48 (41%) 104 (31%)
Low/medium 84 (61%) 70 (59%) 237 (70%)
PTSD <0.0011,2
Lifetime history 63 (46%) 56 (47%) 100 (29%)
No history 75 (54%) 62 (53%) 241 (71%)
Opioid prescription (past year) 0.65
Yes 60 (44%) 46 (40%) 132 (39%)
No 77 (56%) 68 (60%) 205 (61%)
1Signiﬁcance < 0.05 for comparison between OUD and no SUD.
2Signiﬁcance < 0.05 for comparison between nonopioid SUD and no SUD.
Table 3: Logistic regression models of moderate-to-signiﬁcant barriers stratiﬁed by substance use disorder†∗ (N = 597).
Side Eﬀect Addiction Reporting Pain
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Unadjusted
OUD versus No SUD 2.09 (1.37, 3.20) <0.001 2.78 (1.54, 5.00) <0.001 0.83 (0.53, 1.29) 0.41
Nonopioid SUD versus no SUD 1.49 (0.97, 2.29) 0.07 1.20 (0.73, 1.97) 0.48 0.49 (0.29,0.83) 0.01
OUD versus nonopioid SUD 1.40 (0.83, 2.37) 0.21 2.32 (1.16, 4.62) 0.02 1.69 (0.93, 3.10) 0.09
Adjusted
OUD versus no SUD 2.30 (1.44, 3.68) <0.001 2.69 (1.44, 5.03) 0.002 0.82 (0.50, 1.35) 0.44
Non opioid SUD versus no SUD 1.64 (1.02, 2.65) 0.04 1.27 (0.74, 2.19) 0.39 0.43 (0.24,0.76) 0.004
OUD versus nonopioid SUD 1.40 (0.81, 2.43) 0.23 2.12 (1.04, 4.30) 0.04 1.91 (1.01,3.60) 0.045
†Moderate-to-signiﬁcant barriers deﬁned as score of ≥3o ns u b s c a l e( r a n g e0 – 5 ) .
∗Models adjusted for gender, employment, depression, somatic symptom severity, education, race, PTSD, and recent opioid use.Pain Research and Treatment 5
were lower for those with nonopioid SUDs than for those
with no SUDs.
Adjusted Analyses. Multivariate logistic regression analyses
of moderate-to-signiﬁcant attitudinal barrier subscale scores
among participants with OUDs, nonopioid SUDs, and no
SUD are also shown in Table 3.T h eg r e a t e rc o n c e r n sa b o u t
side eﬀects and fear of addiction among participants with
OUDs compared with those with no SUD persisted in
adjusted analyses. Similarly, those with OUDs continued to
report higher fears of addiction and higher concern about
reporting pain as compared to those with nonopioid SUDs.
Diﬀerences in worry about reporting pain to physicians
between those with nonopioid SUDs remained lower than
among those with no SUDs in adjusted analyses. After
adjustment, participants with nonopioid SUDs had higher
concerns about side eﬀects than those with no SUDs,
and participants with OUDs had higher concerns about
reporting pain than those with nonopioid SUDs.
4. Discussion
In our sample of 597 primary care patients with chronic
pain, moderate-to-signiﬁcant fear about side eﬀects and
concern about addiction was common, and more so for
participants with OUDs and nonopioid SUDs than those
with no SUDs. Conversely, moderate-to-signiﬁcant worries
aboutreportingpaintophysicianswerelesscommonoverall,
andlesssoforparticipantswithnonopioidSUDs.Inadjusted
analyses, participants with OUDs reported more concern
about side eﬀects and fear of addiction yet similar worries
about reporting pain to physicians as those with no SUD.
Participants with nonopioid SUDs reported lower worries
about reporting pain to physicians than those with no SUD
and those with OUDs. Interestingly, those with current and
lifetime substance use disorders reported similar barriers
with regard to all three subscales.
Why might people with OUDs and chronic pain report
a greater degree of attitudinal barriers to analgesic use than
participants with nonopioid SUDs? In our study, there were
no diﬀerences in baseline characteristics between those with
OUDs and those with nonopioid SUDs, which suggests
that there is something about the experience of the opioid
itself (such as the potential addictive quality of opioids)
that is associated with increased barriers. Because relapse
or worse addiction may be triggered by exposure to opioid
medications,thosewithOUDsmayhaveheightenedconcern
compared to those with nonopioid SUDs, who may perceive
less risk of addiction with exposure to opioids. This ﬁnding
is consistent with other studies showing that HIV-infected
patients with a prior injection drug use history are more
concerned than their noninjection drug using counterparts
about the addictive potential of pain medications [10].
Greater attitudinal barriers among participants with
OUDs are particularly interesting because this observation
is in contradiction to the experience of many clinicians
who describe patients with pain and opioid abuse as
“drug seeking” [26]. In fact, while the majority of partici-
pants in our study reported attitudinal barriers to analgesic
medications, in a study of physicians’ perceptions of barriers
to AIDS pain management, only a minority of physicians
(24%) believed patient reluctance to take opioids to be a
barrier to pain management [27]. This discrepancy between
physician perception of patient reluctance to take opioids
and patient concerns about taking opioids may be a source
of miscommunication between patients and physicians. In
fact, a clinical encounter for a patient with a substance use
historythatisfocusedonpainmayhavecompetingdemands
on the part of both the clinician and the patient. Clinicians
balance ambiguity in pain assessment, treatment goals, and
treatment risks [28]; similarly, though attitudinal barriers
may play a role for the patient, these barriers may not be
expressed due to a desire to obtain pain medications for
pain relief or misuse, including for their euphoric eﬀect or
diversion, all of which are common among patients with
prior substance use disorders [5].
The ﬁnding that attitudinal barriers were similar for
those with current and lifetime opioid use disorders suggests
that patients with past SUDs may harbor as many negative
attitudes regarding concerns about side eﬀects and fear of
addiction potential as patients currently struggling with
opioid addiction. This caution about taking pain medica-
tions in patients with past SUDs and chronic pain may be
appropriate. While opioids may provide good short-term
pain relief, chronic opioid use can produce a number of
problems,includingrelapse[29].However,theseperceptions
may also lead to undertreatment of pain.
Why might individuals with SUDs have lesser attitudinal
barriers to reporting pain to doctors than individuals
without SUDs? Patients in this study all suﬀered from
chronic pain and may therefore have developed a certain
level of comfort discussing pain. In addition, patients in our
study also had ongoing relationships with regular primary
care clinicians, a key characteristic identiﬁed by patients
as essential to good communication and clinical decision
making [30]. Finally, patients with SUDs may ﬁnd it easier to
talk about pain than other areas, such as addiction or mental
health.
Several limitations apply to our ﬁndings. The sample was
derived from a single academic urban hospital primary care
practice and is therefore potentially subject to idiosyncratic
practices, which may limit its generalizability. Nonetheless,
the sample reﬂects a demographically heterogeneous group
and is likely similar to patients in many other urban primary
care practices in the US. In addition, the questions focused
on possible side eﬀects, addiction potential, and reporting of
pain, and not about attitudes towards requesting or receiving
prescriptions for opioid pain medications. Thus, we may
have missed the potentially contentious part of the medical
encounter: namely, the dispensation of opioid prescriptions.
Finally, the questions did not explicitly delineate which
classes of pain medications (e.g., opioid versus nonopioid
analgesics) to consider. We expect that most participants
assumed questions were referring to opioid medications;
indeed recent opioid prescription was common in our sam-
ple, suggesting that many participants had experience with
prescription opioids.6 Pain Research and Treatment
Despite these limitations, the study oﬀers a preliminary
look into the nature of patient attitudinal barriers to anal-
gesic use in primary care patients with pain and addictions.
It also oﬀers an alternative perspective on patient-physician
interactions than that previously described. Prior studies
have demonstrated that the patient-physician interaction
regarding pain medications is characterized by mutual
mistrust and diﬃcult communication [26]. Primary care
providers display discomfort and avoidance in discussing
unhealthy alcohol use [31], suggesting that physicians expe-
rience diﬃculty communicating about substance use. How-
ever, in this study, patients with SUDs reported low atti-
tudinal barriers to reporting pain to clinicians. They also
reported similar concerns to those of physicians, namely,
concernregardingpainmedicationsideeﬀectsandaddiction
potential of these medications [10]. These ﬁndings may
therefore highlight common ground between patients and
physicians that oﬀers a basis for patient-physician alliance
rather than the previously described “mutual mistrust” [26].
5. Conclusions
In summary, patients with opioid use disorders and chronic
pain have greater attitudinal barriers to analgesic use than
those without opioid use disorders. Patients with substance
use disorders have lower attitudinal barriers to reporting
pain to physicians. Given the substantial functional, social,
and psychological consequences of undertreated pain, there
is an imperative for physicians to work with patients
who have comorbid pain and substance use disorders to
address their attitudinal barriers to pain medications. This
study highlights a modiﬁable barrier to eﬀectively treating
chronic pain in patients with SUD. Further clinical care
and research should focus on addressing attitudinal barriers
so that patients may have maximum pain relief without
compromising recovery from addiction.
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